Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 (Spesolimab) bioavailability study in healthy volunteers
NCT03100903Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of spesolimab (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 4200 hours and Maximum Measured Concentration of BI 655130 in Plasma at 4200 hours. Started Apr 2017; status: completed.
02
Drugs
spesolimab
Beyond the preview
Go deeper on NCT03100903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100903.